Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2012 1
2013 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
Huang M, A Fasching P, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, Cappoen N, O'Shaughnessy J. Huang M, et al. Among authors: le bailly de tilleghem c. Adv Ther. 2023 Mar;40(3):1153-1170. doi: 10.1007/s12325-022-02365-1. Epub 2023 Jan 17. Adv Ther. 2023. PMID: 36648737 Free PMC article.
Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1.
Huang M, O'Shaughnessy J, Haiderali A, Pan W, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, Cappoen N, Fasching PA. Huang M, et al. Among authors: le bailly de tilleghem c. Eur J Cancer. 2022 Dec;177:45-52. doi: 10.1016/j.ejca.2022.09.029. Epub 2022 Oct 3. Eur J Cancer. 2022. PMID: 36323052 Clinical Trial.
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW, Le Bailly De Tilleghem C. Webb NJ, et al. Among authors: le bailly de tilleghem c. Nephrol Dial Transplant. 2011 Aug;26(8):2521-6. doi: 10.1093/ndt/gfq797. Epub 2011 Feb 1. Nephrol Dial Transplant. 2011. PMID: 21285125 Clinical Trial.
Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D. Bonnick S, et al. Among authors: le bailly de tilleghem c. J Clin Endocrinol Metab. 2013 Dec;98(12):4727-35. doi: 10.1210/jc.2013-2020. Epub 2013 Sep 24. J Clin Endocrinol Metab. 2013. PMID: 24064689 Clinical Trial.
Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Dasilva C, Rosenberg E, Leung A. Langdahl B, et al. Among authors: le bailly de tilleghem c. J Bone Miner Res. 2012 Nov;27(11):2251-8. doi: 10.1002/jbmr.1695. J Bone Miner Res. 2012. PMID: 22777865 Free article. Clinical Trial.